Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Gains from Sales and Divestitures (2016 - 2025)

Jaguar Health (JAGX) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $1292.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $1292.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1292.0, a N/A change, with the full-year FY2017 number at $20789.0, down 25.13% from a year prior.
  • Gains from Sales and Divestitures was $1292.0 for Q3 2025 at Jaguar Health, up from $4.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1292.0 in Q3 2025 to a low of $4.0 in Q2 2025.